 |
| 26-Apr-13 | Reiterated |
Barclays |
Overweight |
$113 → $132 |
|
| 22-Apr-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$121 → $142 |
|
| 05-Apr-13 | Upgrade |
Deutsche Bank |
Hold → Buy |
$105 → $143 |
|
| 25-Mar-13 | Downgrade |
WallachBeth |
Buy → Hold |
|
|
| 04-Mar-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$115 → $121 |
|
| 12-Feb-13 | Reiterated |
Barclays |
Overweight |
$102 → $111 |
|
| 28-Jan-13 | Downgrade |
Argus |
Buy → Hold |
|
|
| 25-Jan-13 | Reiterated |
Barclays |
Overweight |
$94 → $102 |
|
| 23-Jan-13 | Reiterated |
Stifel Nicolaus |
Buy |
$98 → $108 |
|
| 14-Jan-13 | Reiterated |
Cantor Fitzgerald |
Buy |
$96 → $115 |
|
| 08-Jan-13 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$90 → $100 |
|
| 08-Jan-13 | Reiterated |
WallachBeth |
Buy |
$89 → $99 |
|
| 08-Jan-13 | Reiterated |
Stifel Nicolaus |
Buy |
$89 → $98 |
|
| 08-Jan-13 | Reiterated |
Barclays |
Overweight |
$87 → $94 |
|
| 08-Jan-13 | Reiterated |
Argus |
Buy |
$88 → $95 |
|
| 04-Jan-13 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$85 → $90 |
|
| 12-Nov-12 | Reiterated |
Cantor Fitzgerald |
Buy |
$82 → $96 |
|
| 15-Oct-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 21-Sep-12 | Reiterated |
Argus |
Buy |
$75 → $88 |
|
| 10-Sep-12 | Downgrade |
UBS |
Buy → Neutral |
$78 → $80 |
|
|
|
| 23-May-13 02:04PM | Amgen Stock Checkup for May at Motley Fool |
| 01:47PM | Midday Glance: Biotechnology companies AP |
| 01:03PM | 5 Stocks Raising The Drugs Industry Higher at TheStreet |
| 12:09PM | Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer Business Wire |
| 12:07PM | Jim Cramer: Buy Biogen Idec, Celgene, Clean Harbors, and This Stock at Wall St. Cheat Sheet |
| 11:07AM | McDonalds Initiates a Dividend, Seagate Gets An Upgrade, and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 10:46AM | Early Glance: Biotechnology companies AP |
| 09:40AM | Stocks to Watch: Hewlett-Packard, Pacific Sunwear, Ralph Lauren at The Wall Street Journal |
| 07:31AM | InPlay: Celgene announces U.S. FDA grants priority review for ABRAXANE sNDA in advanced pancreatic cancer Briefing.com |
| 07:30AM | Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer Business Wire |
| 22-May-13 06:08PM | Final Glance: Biotechnology companies AP |
| 05:53PM | Bristol-Myers, Jazz Pharmaceuticals Lead Pharma Rally at Investor's Business Daily |
| 05:20PM | Stocks Reverse Lower On Fears That Fed May Pare Easing at Investor's Business Daily |
| 03:55PM | Gilead's Sofosbuvir under European Review Zacks |
| 02:38PM | Celgene's Management Presents at UBS Global Healthcare Conference (Transcript) Seeking Alpha |
| 02:38PM | Celgene's Management Presents at 2013 UBS Global Healthcare Conference (Transcript) Seeking Alpha |
| 01:18PM | Buy Bristol-Myers, Says Citi; Stock Jumps 7% at Barrons.com |
| 01:17PM | Midday Glance: Biotechnology companies AP |
| 12:09PM | Stocks Stage Broad Advance; Bristol-Myers Leads Medicals at Investor's Business Daily |
| 10:51AM | Early Glance: Biotechnology companies AP |
| 21-May-13 08:50PM | Final Glance: Biotechnology companies AP |
| 03:56PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 02:22PM | Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Opportunities in Hepatitis C and Genomic Technologies Wall Street Transcript |
| 02:00PM | Are These The Ultimate Growth And Value Plays? StreetAuthority Network |
| 02:00PM | Are These The Ultimate Growth And Value Plays? |
| 01:16PM | Midday Glance: Biotechnology companies AP |
| 10:36AM | Early Glance: Biotechnology companies AP |
| 12:24AM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 12:04AM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 20-May-13 11:07PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 09:06PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 06:05PM | Final Glance: Biotechnology companies AP |
| 04:57PM | Celgene, Visa, Apple: Rob Bartolo's Likes, Dislikes at Investor's Business Daily |
| 01:16PM | Midday Glance: Biotechnology companies AP |
| 11:58AM | Cramer: A Pile of Simply Horrendous Advice at TheStreet |
| 10:31AM | Early Glance: Biotechnology companies AP |
| 17-May-13 06:03PM | Final Glance: Biotechnology companies AP |
| 05:00PM | Celgene Corporation (CELG): Today's Featured Health Care Winner at TheStreet |
| 01:32PM | Midday Glance: Biotechnology companies AP |
| 11:07AM | Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to Investing Wall Street Transcript |
| 10:25AM | Early Glance: Biotechnology companies AP |
| 16-May-13 07:00PM | Todays 3 Worst Stocks at Motley Fool |
| 06:03PM | Final Glance: Biotechnology companies AP |
| 05:18PM | Stocks Close Lower; Dell Little Changed After Earnings at Investor's Business Daily |
| 05:00PM | [video] Stock Pops & Drops at CNBC |
| 04:23PM | Wall Street Turns Down At The Bell; Celgene Sells Off at Investor's Business Daily |
| 03:29PM | Gilead Drug For Leukemia Shows Success In Early Trial at Investor's Business Daily |
| 03:26PM | Stocks Flat In Late Trading, But Cisco Lifts Nasdaq at Investor's Business Daily |
| 02:05PM | 3 Companies That Put the "Tech" in "Biotech" at Motley Fool |
| 01:52PM | Stocks Little Changed; Qihoo, Ocwen Hit New Highs at Investor's Business Daily |
| 01:29PM | Midday Glance: Biotechnology companies AP |
| 01:23PM | Investing in Health Care Innovation: A Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund Wall Street Transcript |
| 01:04PM | AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward at TheStreet |
| 11:50AM | Celgene, Gilead lower after new data published at ASCO at theflyonthewall.com |
| 10:35AM | Early Glance: Biotechnology companies AP |
| 15-May-13 06:02PM | Final Glance: Biotechnology companies AP |
| 02:00PM | Myriad Soars Higher on Celeb Clout Zacks |
| 01:26PM | Midday Glance: Biotechnology companies AP |
| 12:46PM | Jim Cramer: Buy AOL, Celgene, Biogen, and This Hot Stock Now at Wall St. Cheat Sheet |
| 10:24AM | Early Glance: Biotechnology companies AP |
| 09:31AM | [video] Cramer's '4 Horsemen of the Apocalypse' for Shorts at CNBC |
| 09:30AM | Wider-Than-Expected Loss at Athersys Zacks |
| 08:00AM | Manatt, Jones Day, Howrey, Ropes & Gray: Business of Law at Bloomberg |
| 14-May-13 06:02PM | Final Glance: Biotechnology companies AP |
| 06:00PM | Jim Cramer's 5 Investing Sweet Spots at CNBC |
| 06:00PM | [video] Investing in a Market at All-Time Highs at CNBC |
| 05:23PM | MainStay Large Cap Growth Nibbles On Apple at Investor's Business Daily |
| 02:10PM | Midday Glance: Biotechnology companies AP |
| 12:50PM | Celgene: Apremilast For Psoriatic Arthritis Offers Upside at Seeking Alpha |
| 12:13PM | Celgene Attains 52-Week High Zacks |
| 10:36AM | Early Glance: Biotechnology companies AP |
| 08:58AM | Morning Read: Biotech Under the Microscope at Barrons.com |
| 06:10AM | [$$] Biotech Fund: Many Healthy Returns at Barrons.com |
| 13-May-13 11:56PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 10:52PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 10:02PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 09:30PM | [$$] Credits & Debits | cfoeditors@wsj.com at The Wall Street Journal |
| 06:02PM | Final Glance: Biotechnology companies AP |
| 05:40PM | Setback for Endo Health on Opana ER Zacks |
| 05:36PM | Top-Rated Big-Cap Stocks Rising With Robust Market at Investor's Business Daily |
| 04:34PM | Stocks End Mixed In Quiet Trade; Stratasys Leads 3D Rally at Investor's Business Daily |
| 02:00PM | Just Face it, You'll Never Invest Like Warren Buffett--Nor Should You at Motley Fool |
| 01:50PM | Genomic Gains Coverage for DCIS Zacks |
| 01:18PM | Midday Glance: Biotechnology companies AP |
| 10:38AM | Celgene Stock Hits New 52-Week High (CELG) at TheStreet |
| 10:23AM | Early Glance: Biotechnology companies AP |
| 08:52AM | 3 Earnings Reports That Caught My Attention Last Week at Motley Fool |
| 12-May-13 06:21PM | Part 2: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company? at Seeking Alpha |
| 11-May-13 08:06AM | Actavis Joins Other Drugmakers On Elite IBD 50 at Investor's Business Daily |
| 10-May-13 06:34PM | Green Mountain's Big Jump Lends A Boost To IBD 50 at Investor's Business Daily |
| 06:02PM | Final Glance: Biotechnology companies AP |
| 04:39PM | Cramer: Biotech Makes a Comeback at TheStreet |
| 01:20PM | Midday Glance: Biotechnology companies AP |
| 12:52PM | Biotech Makes a Comeback TheStreet |
| 10:31AM | Early Glance: Biotechnology companies AP |
| 09-May-13 10:02PM | Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived at Seeking Alpha |
| 06:10PM | Biotech Stocks Dominate Your Weekly Review List at Investor's Business Daily |
| 06:03PM | Final Glance: Biotechnology companies AP |
| 04:06PM | NeoStem CEO's Letter to Shareholders GlobeNewswire |
| 03:30PM | Positive Data on Celgene's Apremilast Zacks |
|
|
| Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Its commercial stage products include REVLIMID, an oral immunomodulatory drug to treat patients with multiple myeloma and transfusion-dependent anemia; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk myelodysplastic syndromes (MDS), as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for the treatment of solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia in patients with blood disorders. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc. to discover, develop, and commercialize gene therapies in oncology; FORMA Therapeutics Holdings to discover, develop, and commercialize drug candidates to regulate protein homeostasis; and Concert Pharmaceuticals, Inc. to develop deuterium-modified compounds for cancer and inflammation. The company was founded in 1980 and is headquartered in Summit, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| CASEY MICHAEL D | Director | Apr 30 | Option Exercise | 11.21 | 9,294 | 104,163 | 9,294 | May 01 04:06 PM | | CASEY MICHAEL D | Director | Apr 30 | Sale | 118.07 | 9,294 | 1,097,354 | 19,458 | May 01 04:06 PM | | CASEY MICHAEL D | Director | Apr 29 | Option Exercise | 11.21 | 5,706 | 63,950 | 5,706 | May 01 04:06 PM | | DRAKE RODMAN L | Director | Apr 29 | Option Exercise | 38.43 | 1,000 | 38,430 | 17,363 | May 01 04:07 PM | | CASEY MICHAEL D | Director | Apr 29 | Sale | 120.11 | 5,706 | 685,323 | 19,458 | May 01 04:06 PM | | DRAKE RODMAN L | Director | Feb 04 | Buy | 98.50 | 400 | 39,399 | 16,363 | Feb 06 04:16 PM | | HUGIN ROBERT J | see remarks | Dec 18 | Option Exercise | 25.68 | 20,172 | 517,916 | 458,298 | Dec 19 06:47 PM | | KAPLAN GILLA | Director | Dec 11 | Option Exercise | 8.41 | 48,000 | 403,440 | 54,055 | Dec 13 04:30 PM | | KAPLAN GILLA | Director | Dec 11 | Sale | 81.42 | 32,400 | 2,637,891 | 21,655 | Dec 13 04:30 PM | | DRAKE RODMAN L | Director | Nov 14 | Option Exercise | 38.43 | 1,000 | 38,430 | 15,963 | Nov 16 04:00 PM | | CASEY MICHAEL D | Director | Jun 22 | Option Exercise | 11.28 | 12,000 | 135,330 | 19,458 | Jun 26 04:17 PM |
|
|
|
|
|
|
